Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years

Akira Kajiwara¹, Keiichi Kinowaki², Norio Akuta¹, Kayoko Kasuya¹, Nozomu Muraishi¹, Soichi Iritani¹, Yusuke Kawamura¹, Shunichiro Fujiiyama¹, Hitomi Sezaki¹, Tetsuya Hosaka¹, Satoshi Saitoh¹, Masahiro Kobayashi¹, Mariko Kobayashi¹, Yasuji Arase¹, Kenji Ikeda¹, Fumitaka Suzuki¹, Hiromitsu Kumada¹ and Yoshiyuki Suzuki¹

Abstract:
We report a 71-year-old man with non-B non-C chronic liver damage who had been regularly visiting our hospital since he was 38 years of age. He underwent three partial hepatectomies for HCC diagnosed at 65, 67, and 71 years of age, respectively. A histopathologicalexamination showed moderately-differentiated HCC, and chronic hepatitis with mild fibrosis stage in non-tumor areas. AFP and PIVKAII were not useful for the early prediction of HCC, but TERT promotor mutation (C228T) in serum cell-free DNA was useful. This is the first report on the importance of long-term follow-up in non-B non-C chronic liver damage, regardless of the fibrosis stage.

Key words: hepatocellular carcinoma, non-B non-C, mild fibrosis stage, TERT promoter, cell-free DNA, Wild-type blocking PCR

(Intern Med Advance Publication)
(DOI: 10.2169/internalmedicine.5055-20)

Introduction

The main causes of hepatocellular carcinoma (HCC) are hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in both Japan and most other countries (1, 2). The development of HCC correlates with the progression of liver fibrosis, and the rate of future carcinogenesis is predicted by the degree of fibrosis (3, 4). HCC is rare in subjects with normal or mild fibrosis of the liver (5-8). We herein report triplet HCCs, diagnosed at ages 65, 67 and 71 years in a patient with non-B non-C liver injury and mild fibrosis. Each tumor was excised surgically soon after diagnosis and thereafter was examined histopathologically.

Case Report

The patient was a 71-year-old man who had been regularly visiting our hospital for about 30 years due to chronic liver disease. On the first consultation at 38 years of age, he had no other remarkable medical history. HBV surface antigen was negative, but HBV surface antibody and HBV core antibody were positive. HCV antibody was negative. Antinuclear antibody and anti-mitochondrial antibody were negative, and alcohol consumption was less than 20 g/day (namely, non-B non-C liver damage). The established diagnosis was non-alcoholic fatty liver disease diagnosed by ultrasonography and a past history of HBV infection. Treatment included advice to refrain from alcohol drinking and diet/exercise therapy. Subsequent follow-up showed an improvement of the liver damage based on the results of blood tests, including an improvement of fatty liver as confirmed by abdominal ultrasonography (US). The patient was followed-up annually by abdominal US and/or dynamic computed tomography (CT).

Liver function tests showed a progressive decrease in the
γGTP levels, but they subsequently improved to normal levels, while AST and ALT remained persistently close to the upper normal or slightly abnormal (Fig. 1). There was no significant change in body weight since first consultation, and blood tests did not show any increase in either alpha-fetoprotein (AFP) or PIVKAI (Table).

At 65 years of age, a follow-up abdominal US showed a solitary liver tumor at S5. A confirmatory dynamic CT identified the tumor in S5 measuring 20×18-mm in size, with a contrast effect in the arterial phase and washout in the portal vein phase. EOB-MRI showed a highly heterogeneous mass on T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI), and no uptake in the hepatobiliary phase. Based on these features, the tumor was diagnosed as HCC. The patient underwent S5 partial hepatectomy and a histopathological examination of the resected tumor showed moderately organized HCC (negative surgical margin and no vascular invasion), with features of chronic hepatitis (CH) (fibrosis 1 / activity 1 (F1/A1)) in the non-tumorous areas.

At 67 years of age, a new liver tumor was detected at S7 on annual screening abdominal US. Dynamic CT showed a 20×20×15-mm tumor in the S7 segment of the liver, with a contrast effect in the arterial phase and washout in the portal vein phase. EOB-MRI showed a highly heterogeneous mass on T2WI and DWI, and no uptake in the hepatobiliary phase. The new tumor was accordingly diagnosed to be HCC and was consequently excised through S7 partial hepatectomy. Histopathologically, the resected tumor showed moderately organized HCC (negative surgical margin and no vascular invasion), surrounded by CH (F1/A1) non-tumor tissue.

At 71 years of age, another solitary HCC was diagnosed in the liver at segment S8 measuring 18 mm×18 mm×14 mm in size on dynamic CT and EOB-MRI. The contrast pattern was not different from the previous one. He underwent S8 partial hepatectomy and a histopathological examination of the excised specimen showed moderately organized HCC (negative surgical margin and no vascular invasion) with CH (F1/A1) in the non-tumor surrounding tissue. The postoperative clinical course was uneventful and the patient is still alive with no signs of recurrence several months after the third surgery.

Before the three partial hepatectomies, no differences were noted in the contrast pattern between the CT and MRI. All tumor specimens were moderately differentiated HCC e.g., fc(+), s0, vp0, vv0, va0, b0, im0, p0, sm(-) (Fig. 2). Furthermore, the non-tumor tissue in the specimen showed <3% steatosis and mild fibrosis (F1) (Fig. 3).

Recently, we developed a highly sensitive method for the detection of TERT promoter mutations using wild-type blocking PCR (WTB-PCR), combined with Sanger sequencing, and demonstrated its clinical usefulness for the early prediction of HCC by measuring TERT C228T in serum cell-free DNA (cfDNA). The sequencing analysis of WTB-PCR product demonstrated a detection limit in excess of 0.7% Mutant-type DNA in the background of Wild-type DNA (9). In the present case, the relationship between HCC and TERT C228T in serum cfDNA was serially examined by WTB-PCR. TERT C228T was negative before the diagnosis of HCC 64 years of age, but it became positive at the time that HCC was diagnosed, namely when the patient was 65 years of age (Fig. 4).
To the best of our knowledge, this is the first report on the importance of a long-term follow-up in non-B non-C chronic liver damage, regardless of the fibrosis stage. Furthermore, this report described three separate onsets of HCC which were diagnosed, excised surgically, and examined histopathologically in a single middle-aged patient within the span of 6 years. The histopathological findings of all three tumors were moderately differentiated HCCs with non-B non-C liver damage and mild fibrosis. While several studies of HCC with a background of non-B non-C liver damage and normal or mild fibrotic liver have been reported (5-8), triple hepatocarcinogenesis is rare. In our patient, all three of the tumors were solitary, measuring ≤20 mm in diameter, with a relatively long inter-new-tumor interval, and all showed moderate differentiation with well-differentiated features in some. Based on these features, we consider all three of these to be new tumors, arising at the age of 65, 67 and 71, rather than for the latter two to be intrahepatic metastases (10, 11).

The pathomechanisms involved in HCC development in this patient are not clear at present. A recent study of 2,087
Japanese patients with HCC indicated that non-viral etiologies (non-B non-C) increased from 10.0% in 1991 to 32.5% in 2015. The significant risk factors for HCC in these patients were old age, obesity, diabetes mellitus, hypertension, dyslipidemia, and fatty liver (1). In our patient with a non-viral etiology, the potential risk factors for HCC are age and a history of fatty liver. Our patient also had a history of HBV infection, and thus a direct oncogenic role of HBV on HCC cannot be ruled out. Bralet et al. (5) retrospectively analyzed 80 patients in whom the non-tumor liver tissue samples showed no or minimal portal fibrosis without any septal fibrosis. The same study concluded that in most cases, the etiologic factors were unidentifiable, although presence of HBV infection in 21% suggested a direct oncogenic role of this virus (5). Thus, the integration of HBV into host DNA might result in a dysregulated expression of the genes involved in cell cycle regulation (3, 12, 13). Further studies of patients who develop HCC with mild fibrosis are needed to investigate the mechanism of HCC development.

In this case, AFP and PIVKAII, which are tumor markers of HCC, were not useful for the early prediction of HCC. The long-term follow-up demonstrated the clinical usefulness of analyzing TERT C228T in the serum cfDNA for the early prediction of HCC (9). The limitations associated with the present study include the lack of an analysis of the relationships between serum TERT C228T and the curability of HCC, and between TERT C228T in the serum and HCC tissue. Especially, a TERT mutation in the serum after the curative resection of HCC should be investigated. In this case, at several points after triplet partial hepatectomy, TERT C228T was confirmed to be positive (data not shown). Regrettably, it was not regularly measured after resection every month, so we could not determine whether a positive TERT C228T finding might have continued regardless of the curability of HCC. This finding might suggest the existence of subclinical HCC. However, the clinicopa-
This type of HCC.

will make it possible to achieve a better understanding of continued to rise in recent years and the report of further cases portion of HCC patients with non-viral etiologies has con-

promoter mutations (14). New WTB-PCR-based highly-sensitive methods for the detection of TERT promoter mutation, including both TERT C228T and C250 T, should therefore be developed in the future. Further stud-

tes of a large number of patients should be performed to in-

vestigate the association between TERT promoter mutation and HCC arising from non-B non-C. In addition, it is true that there are HCCs that are not mediated by TERT promoter mutation (14), and the development of an early diagnost-

cologic modality for such cases is also expected. To the best of our knowledge, this is the first report on thological data in Table showed that the first operation was curative with a negative surgical margin and no vascular invasion. The following HCCs, which may have existed at the time of the first operation, were not detected on mage find-

ings with abdominal US, dynamic CT, and/or EOB-MRI. Apart from the fact that we only described a single patient, another limitation associated with the present study is the lack of an analysis of TERT C250T mutations, as another hotspot of TERT promoter mutations (14).

Fig. 4. Relationship between hepatocellular carcinoma (HCC) and TERT C228T in the serum cell-free DNA, examined serially using wild-type blocking PCR. TERT C228T was negative before the diagnosis of HCC at 64 years of age, but it became positive at the time that HCC was diagnosed at 65 years of age. The wild peak at position 228 (228C) is shown as the blue peak. The mutant peak at position 228 (228T) (red peak) detected at frequency of 0.7% or higher (Positive), but not at 0.6% (Negative). Three red arrows indicated the red mutant peak.

Author’s disclosure of potential Conflicts of Interest (COI). Hiromitsu Kumada: Honoraria, MSD K.K., Gilead Sciences, AbbVie Inc., Eisai Co., Ltd and Dainippon Sumitomo Pharma. Norio Akuta: Honoraria, AbbVie Inc and Gilead Sciences. Yasuji Arase: Honoraria, AbbVie Inc. Masahiro Kobayashi: Honoraria, Eisai Co., Ltd.

Funding: This study was supported in part by a Grant-in-Aid from the Japan Agency for Medical Research and Development to NA (#JP20fk0210065, #JP20fk0210040) and a Grant-in-Aid for scientific research and development from the Ministry of Health, Labour and Welfare of Japan to NA (#19HC1001).

References

1. Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 up-

date. J Gastroenterol 54: 367-376, 2019.

2. Yuen MF, Hou JL, Chatapitti A; Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia Pacific region. J Gastroenterol Hepatol 24: 346-352, 2009.

3. Chauhan R, Lahiri N. Tissue and serum associated biomarkers of hepatocellular carcinoma. Biomarkers in Cancer 32: 200-204, 2016.

4. Sakamoto M, Effendi K, Masugi Y. Molecular diagnosis of multi-

stage hepatocarcinogenesis. Jpn J Clin Oncol 40: 891-896, 2010.

5. Bralet MP, Regimbeau JM, Pineau P, et al. Hepatocellular carcino-

ma occurring in nonfibrotic liver: epidemiologic and histopa-

thologic analysis of 80 French cases. Hepatology 32: 200-204,
6. Ogasawara N, Saitoh S, Denpou H, et al. Poorly differentiated hepatocellular carcinoma in a low-risk patient with an otherwise normal liver. Intern Med 59: 365-372, 2020.

7. Naganuma H, Ishida H, Ogawa M, et al. Hepatocellular carcinoma in otherwise sonographically normal liver. J Clin Ultrasound 47: 325-330, 2019.

8. Komiyama S, Okazaki H, Nakao S, et al. Diffuse fatty metamorphosis of large, well-differentiated hepatocellular carcinoma originating in the normal liver: Case report and literature review. Clin J Gastroenterol 8: 345-350, 2015.

9. Akuta N, Suzuki F, Kobayashi M, et al. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma. J Med Virol 2020 [Epub ahead of print].

10. Ikeda K, Arase Y, Kobayashi M, et al. Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: A long term cohort study of 892 patients with viral cirrhosis. J Gastroenterol 38: 865-876, 2003.

11. Ueno S, Aoki D, Maeda T, et al. Preoperative assessment of multicentric occurrence in synchronous small and multiple hepatocellular carcinoma based on image-patterns and histological grading of non-cancerous region. Hepatol Res 29: 24-30, 2004.

12. Dejean A, Bouguèleret L, Grzeschik KH, et al. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature 322: 70-72, 1986.

13. Wang J, Chenesvesse X, Henglein B, et al. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 343: 555-557, 1990.

14. Chen YL, Jeng YM, Chang CN, et al. TERT promoter mutation in resectable hepatocellular carcinomas: A strong association with hepatitis C infection and absence of hepatitis B infection. Int J Surg 12: 659-665, 2014.